Nuclear Medicine: Page 28

PET tracers can verify patient response to HIFU treatment

By Will Morton

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-5 | Room N226In this molecular oncologic imaging presentation, researchers will report on the use of gallium-68-based radiotracers to assess response to high-intensity focused ultrasound (HIFU) therapy in prostate cancer patients.

November 22, 2021

Combining radiomics, AI with PET/MRI helps assess nodal status

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-3 | Room N226Here, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.

November 21, 2021

Monrol and MTTI ink Lu-177 supply deal

By AuntMinnie.com staff writers

EczacıbaŞı-Monrol Nuclear Products has signed an agreement to supply Molecular Targeting Technologies (MTTI) with no-carrier-added lutetium-177 (Lu-177).

November 18, 2021

NorthStar to buy accelerator for actinium-225 production

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes has inked a deal with Ion Beam Applications (IBA) to purchase one of IBA's Rhodotron TT300 HE electron-beam accelerators for the commercial production of actinium-225 (Ac-225) at its new production facility in Beloit, WI.

November 17, 2021

Emory's Meltzer tapped to lead USC medical school

By AuntMinnie.com staff writers

Dr. Carolyn Meltzer of Emory University has been named as dean of the Keck School of Medicine at the University of Southern California (USC).

November 16, 2021

MIM gets FDA nod for molecular radiotherapy software

By AuntMinnie.com staff writers

Medical imaging software developer MIM software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SurePlan MRT molecular radiotherapy software.

November 16, 2021

PET/MRI shows prowess for nodal staging in breast cancer

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-4 | Room TBAIn this presentation, researchers will compare nodal staging between CT, MRI, and FDG-PET/MRI in patients with newly diagnosed breast cancer.

November 15, 2021

Combining radiomics, AI with PET/MRI helps assess nodal status

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-3 | Room TBAHere, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.

November 15, 2021

Combining radiomics, AI with PET/MRI helps assess nodal status

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01‐3 | Room TBAHere, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.

November 14, 2021

ANSTO to partner with Cyclotek on theranostics facility

By AuntMinnie.com staff writers

The Australian Nuclear Science and Technology Organisation (ANSTO) is entering into a joint venture with Cyclotek to build a new theranostics facility in Melbourne.

November 11, 2021

Clarity hits milestone in study of radiopharmaceutical

By AuntMinnie.com staff writers

Clarity Pharmaceuticals, the Australian-based radiopharmaceutical developer, has completed patient recruitment in the dosimetry phase of a study of its theranostic agent with copper-based radioisotopes for treating metastatic castration-resistant prostate cancer.

November 11, 2021

How can the clinical potential of PET/MRI be unlocked?

By Frances Rylands-Monk

Why are some countries lagging behind others when it comes to unlocking the clinical potential of PET/MRI? Cancer imaging expert Dr. Vicky Goh of the U.K. took out her crystal ball and provided some insight into the future role of PET/MRI and how both modalities can be integrated effectively.

November 10, 2021

Previous Page

Page 28 of 438

Next Page